1. OP01 Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE). (21st January 2022) Authors: Louis J, E; Resche-Rigon, M; Laharie, D; Satsangi, J; Ding, N; Preiss, J; D'Haens, G; Picon, L; Bossuyt, P; Vuitton, L; Irving, P; Bouhnik, Y; Viennot, S; Lamb, C; Pollock, R; Baert, F; Nachury, M; Mathurin, F; Gilletta, C; Colombel, J F Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i001 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗